Negative Effect of Pandemic on Cancer Survivorship Will Take Years to Calculate

Negative Effect of Pandemic on Cancer Survivorship Will Take Years to Calculate

Millions of screenings and treatments have been missed resulting in a rise in metastatic cancers. Cancer survivorship has made great strides, with death rates declining 31% since 1991 and oncology clinical trials dominating therapeutic focus. But cancer patients require uninterrupted care, and the full impact on survivorship of disruptions in care caused by the pandemic […]

Read More

April 8th, 2022

CKD3 Summit 2022

The 4th Annual Chronic Kidney Disease Drug Development (CKD3) Summit saw a select group of scientists, clinical researchers and experts from industry and regulatory agencies gathered face-to-face for the first time since the pandemic. Excitement and enthusiasm were evident as these experts networked and collaborated on how the latest scientific research is being applied to […]

Read More

March 30th, 2022

UPcare Group to Commence Human Trials in Australia in the Fight against COVID

The UPcare Group is now advancing to human trials with George Clinical with trials to begin soon. UPcare’s human trials are based on their previous pre-clinical and real-world data. Pre-clinical trial results conducted by The Doherty institute in 2020 indicated that compounds used in UPCare’s formulations and products are up to 99.99% effective at inhibiting […]

Read More

March 15th, 2022

George Clinical Grows Scientific Leadership to Include Latin America with the Addition of Renal Expert Hernán Trimarchi

OVERLAND PARK, KS., March 1, 2022 – George Clinical announces the expansion of its renal scientific leadership into Latin America with the addition of subject matter expert Hernán Trimarchi, MD, PHD, FACP, FASN.   Dr. Trimarchi’s research focuses on glomerular diseases, particularly proteinuria and podocyturia, IgA nephropathy, focal segmental glomerulosclerosis, and Fabry disease. He is Head […]

Read More

March 2nd, 2022

Global and National Scientific Leadership Helps Move Potential Breakthrough CKD Anemia Treatment Forward.

Exceptional kidney and metabolic scientific leadership network provides continuity, communication and cultural expertise in long-term global trial program.   Background The National Institute of Diabetes and Digestive and Kidney Diseases (NIH) estimates that more than one in seven people with kidney disease have anemia, increasing their chance of developing heart problems and strokes. The prevalence […]

Read More

February 3rd, 2022

George Clinical Accredited for Gene Technology Clinical Research

SYDNEY, February 2, 2022 – George Clinical announces that the organization has been accredited by the Australian Office of the Gene Technology Regulator (OGTR) which allows it to be a licence holder for studies involving the use of genetically modified organisms (GMOs).  The addition of this capability  means that George Clinical can now, under the […]

Read More

February 2nd, 2022

George Clinical and Link Health Announce $40M in New Pharma Trials

Eight new pharmaceutical clinical trials with a value of more than $40 million are planned after the New South Wales government in Australia supported a joint venture between George Clinical and Guangzhou (China) based pharmaceutical company Link Health at the 28th biennial NSW-Guangdong Joint Economic Meeting. Minister for Trade and Industry Stuart Ayres said George […]

Read More

January 13th, 2022

George Clinical Receives Frost & Sullivan Best Practices Award for Improving Clinical Trial Efficiency and Patient-Centricity

Based on its recent analysis of the Asia-Pacific clinical contract research organization (CRO) industry, Frost & Sullivan recognizes George Clinical with the 2021 Asia-Pacific Competitive Strategy Leadership Award. As a leading APAC Clinical CRO company, George Clinical formulates solutions with innovation and scientific leadership to produce high-quality outcomes and maintain growth in the evolving CRO […]

Read More

January 13th, 2022

Insight from George Clinical Scientific Team on Leading the Global, Multi-Trial, Long-term ASCEND Program

The ASCEND program assessing the efficacy and safety of daprodustat for the treatment of anemia due to CKD across the CKD disease course is comprised of five Phase III studies. The program has enrolled over 8,000 patients who were treated for up to 4.26 years and spanned more than 35 countries. George Clinical was involved […]

Read More

January 11th, 2022

Noteworthy Renal Research Progress Highlighted by George Clinical Scientific Leaders During ASN Kidney Week

OVERLAND PARK, KS. November 11, 2021 – New kidney and metabolic research involving George Clinical teams and scientific leaders has received global attention during the 2021 American Society of Nephrology’s Kidney Week including contributions featured as abstracts, poster sessions, publications and presentations. Despite the restrictions of a global pandemic, meaningful renal clinical research has advanced […]

Read More

November 12th, 2021

Add George Clinical to your network